Kortmann R-D, Bongartz R, Dieckmann K, Dunst J, Flentje M, Gademann G, Christiansen H, Kamprad F H, Karstens J H, Pape H, Rühl U, Schmidt B F, Willich N, Schulz-Ertner D, Schwarz R, Timmermann B, Pohl F, Klingebiel T, Jürgens H, Rübe C
Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universität Leipzig, Stephanstrasse 9A, 04103 Leipzig.
Klin Padiatr. 2007 May-Jun;219(3):166-72. doi: 10.1055/s-2007-973855.
Radiation therapy is an integral component in the management of childhood malignancies and undergoes a continuous process of optimization within the prospective trials of the GPOH. At present there are approximately 20 active protocols, some specifying radio-oncological study questions, in which about 500 to 600 children annually are given radiotherapy.
MATERIALS/METHODS: The Pediatric Radiation Oncology Working Group (APRO) of the German Society for Radiation Oncology (DEGRO) represents the organizational link between GPOH and DEGRO. Their activities range from phrasing guidelines of radio-oncological therapy, through writing a protocol for a prospective study on radiation-induced late effects (RISK--in co-operation with GPOH, 695 patients registered so far) and organizing meetings for information transfer, to implementing radio-oncology within the prospective studies of the GPOH by establishing study chairs for radio-oncology when radio-oncological questions are a primary focus and/or to function as a reference institution for quality assurance. These activities also include individual case consultations outside the study proper. Twice annually the members of the APRO meet for an update on current knowledge and future directions where a representative of the GPOH is invited to contribute special aspects of pediatric oncology.
In the future, modern technology (intensity modulated radiotherapy, proton therapy, inclusion of imaging in treatment planning) will be part of disease management in pediatric oncology. A working group for modern radiotherapy technology was established to enhance this development. Prospective studies of the GPOH with primary or secondary radio-oncological questions require the implementation of corresponding tasks (documentation, monitoring, etc.) in order to meet future demands on clinical trials and to achieve the aims of the protocol. Consequently adequate financial support is indispensable.
放射治疗是儿童恶性肿瘤治疗的一个重要组成部分，并且在德国儿童肿瘤学研究组（GPOH）的前瞻性试验中不断优化。目前大约有20个正在进行的方案，其中一些规定了放射肿瘤学研究问题，每年约有500至600名儿童接受放射治疗。
材料/方法：德国放射肿瘤学会（DEGRO）的儿科放射肿瘤学工作组（APRO）是GPOH和DEGRO之间的组织联系纽带。其活动范围包括制定放射肿瘤治疗指南，编写关于放射诱导晚期效应的前瞻性研究方案（RISK——与GPOH合作，迄今已登记695例患者）以及组织信息传递会议，通过在放射肿瘤学问题成为主要焦点时设立放射肿瘤学研究主席在GPOH的前瞻性研究中实施放射肿瘤学，和/或作为质量保证的参考机构。这些活动还包括在正式研究之外进行个别病例咨询。APRO成员每年召开两次会议，以了解当前知识和未来方向的最新情况，届时会邀请GPOH的一名代表介绍儿科肿瘤学的特殊方面。
未来，现代技术（调强放射治疗、质子治疗、在治疗计划中纳入影像技术）将成为儿科肿瘤疾病管理的一部分。为此成立了一个现代放射治疗技术工作组以推动这一发展。GPOH针对主要或次要放射肿瘤学问题开展的前瞻性研究需要落实相应任务（记录、监测等），以满足未来对临床试验的要求并实现方案目标。因此，充足的资金支持必不可少。
